Health Catalyst, Inc. (NASDAQ:HCAT) Receives Average Rating of "Hold" from Brokerages

Key Points

• Health Catalyst, Inc. (NASDAQ:HCAT) has received an average rating of "Hold" from twelve brokerage firms, with seven hold recommendations and five buy ratings.
• The average 12-month price target for Health Catalyst shares is $6.18, with notable declines in target prices from firms such as Stifel Nicolaus and Citigroup.
• Approximately 85% of Health Catalyst stock is owned by hedge funds and institutional investors, indicating strong institutional interest in the company.

Shares of Health Catalyst, Inc. (NASDAQ:HCAT - Get Free Report) have earned an average rating of "Hold" from the twelve research firms that are currently covering the stock, MarketBeat Ratings reports. Seven analysts have rated the stock with a hold recommendation and five have issued a buy recommendation on the company. The average 12-month price target among brokerages that have issued ratings on the stock in the last year is $6.1818.

Several equities analysts recently commented on HCAT shares. Stifel Nicolaus reduced their target price on Health Catalyst from $5.50 to $4.50 and set a "hold" rating for the company in a research report on Friday, August 8th. Citigroup cut Health Catalyst from a "buy" rating to a "neutral" rating and dropped their price objective for the stock from $6.50 to $3.50 in a report on Friday, August 8th. Canaccord Genuity Group decreased their target price on Health Catalyst from $10.00 to $9.00 and set a "buy" rating for the company in a research report on Thursday, May 8th. Wells Fargo & Company decreased their target price on Health Catalyst from $10.00 to $6.00 and set an "overweight" rating for the company in a research report on Monday, August 11th. Finally, BTIG Research lowered Health Catalyst from a "buy" rating to a "neutral" rating in a research report on Tuesday, June 17th.

Health Catalyst Stock Performance

Shares of HCAT opened at $3.50 on Wednesday. The company has a current ratio of 1.83, a quick ratio of 1.83 and a debt-to-equity ratio of 0.44. The stock has a 50 day moving average of $3.63 and a 200 day moving average of $4.04. Health Catalyst has a 12 month low of $2.52 and a 12 month high of $9.24. The company has a market capitalization of $246.30 million, a price-to-earnings ratio of -2.32 and a beta of 1.46.

Hedge Funds Weigh In On Health Catalyst

Several institutional investors and hedge funds have recently bought and sold shares of the stock. Group One Trading LLC raised its holdings in Health Catalyst by 107.6% during the fourth quarter. Group One Trading LLC now owns 4,360 shares of the company's stock valued at $31,000 after acquiring an additional 2,260 shares during the period. Cresset Asset Management LLC bought a new stake in Health Catalyst during the second quarter valued at about $39,000. Divergent Planning LLC bought a new stake in Health Catalyst during the second quarter valued at about $45,000. Focus Partners Wealth bought a new stake in Health Catalyst during the first quarter valued at about $46,000. Finally, XTX Topco Ltd bought a new stake in Health Catalyst during the first quarter valued at about $54,000. 85.00% of the stock is currently owned by hedge funds and other institutional investors.

Health Catalyst Company Profile

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.